Meta‑analyses of seven GIGYF2 polymorphisms with Parkinson's disease

Dai,Dongjun; Wang,Yunliang; Zhou,Xingyu; Tao,Jianmin; Jiang,Danjie; Zhou,Hanlin; Jiang,Yi; Pan,Guanghui; Ru,Ping; Ji,Huihui; Li,Jinfeng; Zhang,Yuzheng; Yin,Honglei; Xu,Mingqing; Duan,Shiwei

doi:10.3892/br.2014.324

Meta‑analyses of seven GIGYF2 polymorphisms with Parkinson's disease

Authors:
- Dongjun Dai
- Yunliang Wang
- Xingyu Zhou
- Jianmin Tao
- Danjie Jiang
- Hanlin Zhou
- Yi Jiang
- Guanghui Pan
- Ping Ru
- Huihui Ji
- Jinfeng Li
- Yuzheng Zhang
- Honglei Yin
- Mingqing Xu
- Shiwei Duan
View Affiliations

Affiliations: Zhejiang Provincial Key Laboratory of Pathophysiology, School of Medicine, Ningbo University, Ningbo, Zhejiang 315211, P.R. China, Department of Neurology, The 148 Central Hospital of People's Liberation Army, Zibo, Shandong 255300, P.R. China, Bio‑X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Xuhui, Shanghai 200240, P.R. China
Published online on: July 31, 2014 https://doi.org/10.3892/br.2014.324
Pages: 886-892

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Parkinson's disease (PD) is the second most common neurodegenerative disorder that affects ~2% of the global population aged ≥65 years. Grb10‑interacting GYF protein‑2 (GIGYF2) can influence the development of PD through the regulation of insulin‑like growth factor‑1. The aim of the present meta‑analysis study was to establish the contribution of GIGYF2 polymorphisms to PD. The study was conducted based on nine eligible studies consisting of 7,246 PD patients and 7,544 healthy controls. The results indicated that the GIGYF2 C.3630A>G polymorphism increased the risk of PD by 37% [P=0.008; odds ratio (OR), 1.37; 95% confidence interval (CI), 1.08‑1.73] and that the GIGYF2 C.167G>A polymorphism was significantly associated with PD (P=0.003; OR, 3.67; 95% CI, 1.56‑8.68). The meta‑analyses of the other five GIGYF2 polymorphisms (C.1378C>A, C.1554G>A, C.2940A>G, C.1370C>A and C.3651G>A) did not reveal any significant associations. The present meta‑analyses of the GIGYF2 genetic polymorphisms may provide a comprehensive overview of this PD candidate gene for future studies.

View Figures

View References

1	Van Den Eeden SK, Tanner CM, Bernstein AL, et al: Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. Am J Epidemiol. 157:1015–1022. 2003.
2	Elbaz A, Bower JH, Maraganore DM, et al: Risk tables for parkinsonism and Parkinson’s disease. J Clin Epidemiol. 55:25–31. 2002.
3	Dauer W and Przedborski S: Parkinson’s disease: mechanisms and models. Neuron. 39:889–909. 2003.
4	Mylius V, Engau I, Teepker M, et al: Pain sensitivity and descending inhibition of pain in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 80:24–28. 2009.
5	Grachev ID: Dopamine transporter imaging with [123I]FP-CIT (DaTSCAN) in Parkinson’s disease with depressive symptoms: a biological marker for causal relationships? J Neurol Neurosurg Psychiatry. 85:130–131. 2014.
6	Blonder LX, Slevin JT, Kryscio RJ, et al: Dopaminergic modulation of memory and affective processing in Parkinson depression. Psychiatry Res. 210:146–149. 2013. View Article : Google Scholar : PubMed/NCBI
7	Aarsland D, Zaccai J and Brayne C: A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov Disord. 20:1255–1263. 2005.
8	Gan EC, Lau DP and Cheah KL: Stridor in Parkinson’s disease: a case of ‘dry drowning’? J Laryngol Otol. 124:668–673. 2010.
9	Klebe S, Golmard JL, Nalls MA, et al; French Parkinson’s Disease Genetics Study Group; International Parkinson’s Disease Genomics Consortium (IPDGC). The Val158Met COMT polymorphism is a modifier of the age at onset in Parkinson’s disease with a sexual dimorphism. J Neurol Neurosurg Psychiatry. 84:666–673. 2013.PubMed/NCBI
10	Rode J, Bentley A and Parkinson C: Paraganglial cells of urinary bladder and prostate: potential diagnostic problem. J Clin Pathol. 43:13–16. 1990. View Article : Google Scholar : PubMed/NCBI
11	Najafi MR, Chitsaz A, Askarian Z and Najafi MA: Quality of sleep in patients with Parkinson’s disease. Int J Prev Med. 4(Suppl 2): S229–S233. 2013.
12	Olanow CW and Tatton WG: Etiology and pathogenesis of Parkinson’s disease. Annu Rev Neurosci. 22:123–144. 1999.
13	Wirdefeldt K, Adami HO, Cole P, Trichopoulos D and Mandel J: Epidemiology and etiology of Parkinson’s disease: a review of the evidence. Eur J Epidemiol. 26(Suppl 1): S1–S58. 2011.
14	Vaglini F, Viaggi C, Piro V, et al: Acetaldehyde and parkinsonism: role of CYP450 2E1. Front Behav Neurosci. 7:712013. View Article : Google Scholar : PubMed/NCBI
15	Tanner CM, Ottman R, Goldman SM, et al: Parkinson disease in twins: an etiologic study. JAMA. 281:341–346. 1999. View Article : Google Scholar : PubMed/NCBI
16	Alonso ME, Otero E, D’Regules R and Figueroa HH: Parkinson’s disease: a genetic study. Can J Neurol Sci. 13:248–251. 1986.
17	Pankratz N, Nichols WC, Uniacke SK, et al: Genome-wide linkage analysis and evidence of gene-by-gene interactions in a sample of 362 multiplex Parkinson disease families. Hum Mol Genet. 12:2599–2608. 2003. View Article : Google Scholar : PubMed/NCBI
18	Dai D, Wang Y, Wang L, et al: Polymorphisms of DRD2 and DRD3 genes and Parkinson’s disease: A meta-analysis. Biomed Rep. 2:275–281. 2014.
19	Corti O, Lesage S and Brice A: What genetics tells us about the causes and mechanisms of Parkinson’s disease. Physiol Rev. 91:1161–1218. 2011.PubMed/NCBI
20	Singleton AB, Farrer MJ and Bonifati V: The genetics of Parkinson’s disease: progress and therapeutic implications. Mov Disord. 28:14–23. 2013.
21	Cleary SF and Marciano-Cabral F: Soluble amoebicidal factors mediate cytolysis of Naegleria fowleri by activated macrophages. Cell Immunol. 101:62–71. 1986. View Article : Google Scholar : PubMed/NCBI
22	Morrione A: Grb10 adapter protein as regulator of insulin-like growth factor receptor signaling. J Cell Physiol. 197:307–311. 2003. View Article : Google Scholar : PubMed/NCBI
23	Dufresne AM and Smith RJ: The adapter protein GRB10 is an endogenous negative regulator of insulin-like growth factor signaling. Endocrinology. 146:4399–4409. 2005. View Article : Google Scholar : PubMed/NCBI
24	Russo VC, Gluckman PD, Feldman EL and Werther GA: The insulin-like growth factor system and its pleiotropic functions in brain. Endocr Rev. 26:916–943. 2005. View Article : Google Scholar : PubMed/NCBI
25	Folli F, Ghidella S, Bonfanti L, Kahn CR and Merighi A: The early intracellular signaling pathway for the insulin/insulin-like growth factor receptor family in the mammalian central nervous system. Mol Neurobiol. 13:155–183. 1996. View Article : Google Scholar : PubMed/NCBI
26	Cardona-Gómez GP, Mendez P, DonCarlos LL, Azcoitia I and Garcia-Segura LM: Interactions of estrogens and insulin-like growth factor-I in the brain: implications for neuroprotection. Brain Res Brain Res Rev. 37:320–334. 2001.
27	Picillo M, Erro R, Santangelo G, et al: Insulin-like growth factor-1 and progression of motor symptoms in early, drug-naïve Parkinson’s disease. J Neurol. 260:1724–1730. 2013.PubMed/NCBI
28	Numao A, Suzuki K, Miyamoto M, Miyamoto T and Hirata K: Clinical correlates of serum insulin-like growth factor-1 in patients with Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. Parkinsonism Relat Disord. 20:212–216. 2014.
29	Godau J, Knauel K, Weber K, et al: Serum insulinlike growth factor 1 as possible marker for risk and early diagnosis of Parkinson disease. Arch Neurol. 68:925–931. 2011. View Article : Google Scholar : PubMed/NCBI
30	Wang L, Guo JF, Zhang WW, et al: Follow-up study of variants of the GIGYF2 gene in Chinese patients with Parkinson’s disease. J Clin Neurosci. 18:1699–1701. 2011.PubMed/NCBI
31	Dos Santos AV, Pestana CP, Diniz KR, et al: Mutational analysis of GIGYF2, ATP13A2 and GBA genes in Brazilian patients with early-onset Parkinson’s disease. Neurosci Lett. 485:121–124. 2010.PubMed/NCBI
32	Wang L, Guo JF, Zhang WW, et al: Novel GIGYF2 gene variants in patients with Parkinson’s disease in Chinese population. Neurosci Lett. 473:131–135. 2010.
33	Guo Y, Jankovic J, Zhu S, et al: GIGYF2 Asn56Ser and Asn457Thr mutations in Parkinson disease patients. Neurosci Lett. 454:209–211. 2009. View Article : Google Scholar : PubMed/NCBI
34	Li L, Funayama M, Tomiyama H, et al: No evidence for pathogenic role of GIGYF2 mutation in Parkinson disease in Japanese patients. Neurosci Lett. 479:245–248. 2010. View Article : Google Scholar
35	Cao L, Zhang T, Zheng L, et al: The GIGYF2 variants are not associated with Parkinson’s disease in the mainland Chinese population. Parkinsonism Relat Disord. 16:294–297. 2010.
36	Tan EK, Lin CH, Tai CH, et al: Non-synonymous GIGYF2 variants in Parkinson’s disease from two Asian populations. Hum Genet. 126:425–430. 2009.
37	Nichols WC, Kissell DK, Pankratz N, et al; Parkinson Study Group-PROGENI Investigators. Variation in GIGYF2 is not associated with Parkinson disease. Neurology. 72:1886–1892. 2009. View Article : Google Scholar : PubMed/NCBI
38	Zimprich A, Schulte C, Reinthaler E, et al: PARK11 gene (GIGYF2) variants Asn56Ser and Asn457Thr are not pathogenic for Parkinson’s disease. Parkinsonism Relat Disord. 15:532–534. 2009.PubMed/NCBI
39	Bras J, Simón-Sánchez J, Federoff M, et al: Lack of replication of association between GIGYF2 variants and Parkinson disease. Hum Mol Genet. 18:341–346. 2009. View Article : Google Scholar : PubMed/NCBI
40	Lautier C, Goldwurm S, Dürr A, et al: Mutations in the GIGYF2 (TNRC15) gene at the PARK11 locus in familial Parkinson disease. Am J Hum Genet. 82:822–833. 2008. View Article : Google Scholar : PubMed/NCBI
41	Bonetti M, Ferraris A, Petracca M, Bentivoglio AR, Dallapiccola B and Valente EM: GIGYF2 variants are not associated with Parkinson’s disease in Italy. Mov Disord. 24:1867–1869. 2009.
42	Vilariño-Güell C, Ross OA, Soto AI, et al: Reported mutations in GIGYF2 are not a common cause of Parkinson’s disease. Mov Disord. 24:619–620. 2009.
43	Meeus B, Nuytemans K, Crosiers D, et al: GIGYF2 has no major role in Parkinson genetic etiology in a Belgian population. Neurobiology Aging. 32:308–312. 2011. View Article : Google Scholar : PubMed/NCBI
44	Yu X, Huang Y, Li C, Yang H, Lu C and Duan S: Positive association between lymphotoxin-alpha variation rs909253 and cancer risk: a meta-analysis based on 36 case-control studies. Tumour Biol. 35:1973–1983. 2014. View Article : Google Scholar : PubMed/NCBI
45	Huang Y, Yu X, Wang L, et al: Four genetic polymorphisms of lymphotoxin-alpha gene and cancer risk: a systematic review and meta-analysis. PLoS One. 8:e825192013. View Article : Google Scholar : PubMed/NCBI
46	Tang L, Wang L, Liao Q, et al: Genetic associations with diabetes: meta-analyses of 10 candidate polymorphisms. PLoS One. 8:e703012013. View Article : Google Scholar : PubMed/NCBI
47	Xu X, Wang Y, Wang L, et al: Meta-analyses of 8 polymorphisms associated with the risk of the Alzheimer’s disease. PLoS One. 8:e731292013.
48	Excoffier L, Laval G and Schneider S: Arlequin (version 3.0): an integrated software package for population genetics data analysis. Evol Bioinform Online. 1:47–50. 2007.
49	Coory MD: Comment on: Heterogeneity in meta-analysis should be expected and appropriately quantified. Int J Epidemiol. 39:932–933. 2010. View Article : Google Scholar : PubMed/NCBI
50	Kawalec P, Mikrut A, Wísniewska N and Pilc A: The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol. 32:1415–1424. 2013. View Article : Google Scholar : PubMed/NCBI
51	Giovannone B, Lee E, Laviola L, Giorgino F, Cleveland KA and Smith RJ: Two novel proteins that are linked to insulin-like growth factor (IGF-I) receptors by the Grb10 adapter and modulate IGF-I signaling. J Biol Chem. 278:31564–31573. 2003. View Article : Google Scholar : PubMed/NCBI
52	Laviola L, Giorgino F, Chow JC, et al: The adapter protein Grb10 associates preferentially with the insulin receptor as compared with the IGF-I receptor in mouse fibroblasts. J Clin Invest. 99:830–837. 1997. View Article : Google Scholar : PubMed/NCBI
53	Mori K, Giovannone B and Smith RJ: Distinct Grb10 domain requirements for effects on glucose uptake and insulin signaling. Mol Cell Endocrinol. 230:39–50. 2005. View Article : Google Scholar : PubMed/NCBI
54	Guella I, Pistocchi A, Asselta R, et al: Mutational screening and zebrafish functional analysis of GIGYF2 as a Parkinson-disease gene. Neurobiol Aging. 32:1994–2005. 2011. View Article : Google Scholar : PubMed/NCBI
55	Gasser T: Genetics of Parkinson’s disease. J Neurol. 248:833–840. 2001.
56	Sellbach AN, Boyle RS, Silburn PA and Mellick GD: Parkinson’s disease and family history. Parkinsonism Relat Disord. 12:399–409. 2006.